Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ERCC6L2 antisense RNA 1 (ERCC6L2-AS1) is a long non-coding RNA gene located on human chromosome 9, also known by aliases such as C9orf130 and LINC00476[3][7]. It does not encode a characterized protein and is classified as a non-coding RNA[5]. ERCC6L2-AS1 has been noted as "nasopharyngeal carcinoma-associated gene 12 protein" in some protein prediction databases[5], likely reflecting its identification in expression studies rather than confirmation as a functional protein. Current databases do not provide functional, mechanistic, or drug-interaction data for ERCC6L2-AS1. Its biological roles remain largely uncharacterized; no published experimental evidence details its precise mechanism, disease causality, or utility as a therapeutic target. Some studies indirectly connect it with nasopharyngeal carcinoma, but causal or functional roles have not been validated[5][7]. Thus, ERCC6L2-AS1 should be classified as a long non-coding RNA of unknown function, possibly involved in gene regulatory or epigenetic processes, with putative but unconfirmed relevance in specific cancers, particularly nasopharyngeal carcinoma.
Not applicable; no drugs reported to target ERCC6L2-AS1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ERCC6L2 antisense RNA 1 (ERCC6L2-AS1).